Victoza Market Size, Share & Trends Analysis Report By Indication (Type 2 Diabetes, Obesity Management (Off-Label Use)), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies) and By Region (North America, Europe, Asia-Pacific, Latin America, The Middle East and Africa) Forecasts, 2025-2033

Market Trends

A notable trend influencing the Victoza market is the growing shift toward combination therapies, particularly fixed-ratio combinations like Xultophy, which pairs insulin degludec with liraglutide. This trend aligns with the clinical need for simplified regimens that enhance patient compliance and achieve better glycemic control. As the management of type 2 diabetes becomes increasingly complex, healthcare providers are gravitating toward therapeutic strategies that reduce injection burden while improving efficacy. Victoza’s integration into such combination therapies strengthens its market position by addressing both insulin-dependent and non-insulin-dependent patient segments, making it a versatile option in modern diabetes care protocols.

Another emerging trend is the growing adoption of personalized medicine approaches, where real-world data and digital health platforms are used to optimize GLP-1 therapy based on individual patient profiles. This approach enhances the clinical value of Victoza by enabling more targeted treatment, minimizing adverse events, and improving long-term outcomes. Additionally, the regulatory landscape is evolving rapidly, with global agencies accelerating approvals and embracing data-sharing initiatives that facilitate quicker market access for GLP-1-based drugs and biosimilars. These regulatory shifts, combined with a heightened focus on long-term health economics and cardiovascular outcomes, are shaping prescribing patterns in favor of well-established drugs like Victoza that offer proven, comprehensive benefits across multiple comorbidities.

Victoza Market Growth Factor

One of the primary drivers of growth in the Victoza market is the escalating global prevalence of type 2 diabetes. As of 2021, approximately 537 million adults were living with diabetesa number projected to rise steadily in the coming decades. Victoza's clinically proven efficacy in lowering blood glucose levels and reducing HbA1c positions it as a preferred treatment option among healthcare professionals. Furthermore, its demonstrated cardiovascular benefits, particularly in patients with existing heart disease, have made it a cornerstone therapy in diabetes management. These dual therapeutic advantages not only enhance patient outcomes but also align with updated treatment guidelines that emphasize cardiovascular risk reduction in diabetic care.

Another key driver is the expansion of Victoza’s approved indications, including its use in pediatric patients aged 10 years and older. This regulatory progress allows for earlier intervention in younger populations, addressing a growing concern over childhood obesity and early-onset diabetes. Additionally, Victoza’s role in fixed-ratio combination therapies has broadened its application across diverse patient segments, improving adherence and therapeutic outcomes. Coupled with the global rise in obesity impacting over 650 million adults Victoza's secondary benefit of promoting weight loss further distinguishes it from traditional anti-diabetic therapies. This multifaceted clinical profile enhances Victoza's appeal in both primary and adjunct treatment strategies, fueling sustained market demand.

Market Restraint

The Victoza market faces significant restraints that could impact its growth trajectory over the forecast period. Chief among these is the expiration of its primary patent in major markets, including the United States in 2023. This development opens the door to biosimilar competition, which is expected to exert downward pressure on pricing and erode Victoza’s market share, particularly in cost-sensitive segments. Additionally, the high cost of therapy remains a major barrier in low- and middle-income countries, where limited access to insurance coverage or government subsidies restricts widespread adoption. Despite its clinical efficacy, affordability challenges continue to limit Victoza’s reach among underserved populations.

Another critical restraint is the increasing competition from newer GLP-1 receptor agonists such as semaglutide, marketed as Ozempic for diabetes and Wegovy for obesity. These newer agents offer superior glycemic control and weight reduction outcomes, often with more convenient dosing regimens (e.g., weekly injections), making them more appealing to both physicians and patients. Furthermore, Victoza’s injectable delivery format remains a hurdle for individuals with needle aversion, especially as oral GLP-1 options like Rybelsus gain traction. This combination of evolving therapeutic alternatives and patient preferences presents a growing threat to Victoza’s position in the GLP-1 market.

Market Opportunity

The Victoza market presents several promising opportunities that can be leveraged to sustain and potentially accelerate growth, particularly in emerging economies. One of the most impactful avenues lies in the development and commercialization of liraglutide biosimilars. As Victoza's patents expire, biosimilar manufacturers have the opportunity to produce more affordable alternatives, thereby improving access in underserved regions such as Asia and Latin America, where high treatment costs have historically limited uptake. This cost-efficiency could significantly expand the patient base and support broader disease management initiatives driven by governments and non-governmental health organizations.

In parallel, the expansion of digital health ecosystems offers valuable strategic opportunities. Collaborations with digital health platforms and remote monitoring services can enhance patient adherence by providing real-time support and personalized treatment tracking. This is especially relevant in the post-pandemic era, where telemedicine has become a mainstream healthcare delivery channel. Furthermore, Victoza’s pediatric approval for patients aged 10 and older presents a largely untapped segment, particularly in regions experiencing a surge in childhood obesity and early-onset diabetes. Integrating Victoza into pediatric treatment regimens, supported by telehealth tools, not only broadens its clinical footprint but also enhances its long-term positioning as a foundational therapy in chronic disease management.

Indication Insights

The Victoza market can be segmented by indication, with type 2 diabetes representing its dominant application. In 2024, the type 2 diabetes segment accounted for approximately USD 4.4 billion in market value and is projected to grow at a CAGR of 5.9% through 2030. This sustained growth is driven by Victoza’s well-established clinical profile, including robust data supporting glycemic control, cardiovascular risk reduction, and long-term safety. Its inclusion in key international treatment guidelines, such as those issued by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD), further solidifies its position as a frontline therapy in type 2 diabetes management. Conversely, Victoza's off-label use for obesity management accounted for USD 0.9 billion in 2024, with a higher projected CAGR of 9.2%. This growth reflects rising adoption among patients with obesity and metabolic syndrome who benefit from Victoza’s weight-reducing effects. However, the segment may experience moderate deceleration in later years as newer, more targeted anti-obesity drugs like Wegovy continue to capture market share due to superior efficacy and regulatory approvals.

Distribution Channel Insights

By distribution channel, hospital pharmacies held the largest share of the Victoza market in 2024, accounting for 42%. These settings typically serve high-risk patients requiring close monitoring and allow for bulk procurement and streamlined administration, especially in inpatient care. Retail pharmacies followed with a 35% share, reflecting increased patient preference for convenience, ongoing prescriptions, and the ability to administer injections at home. This channel is also supported by pharmacist-led diabetes management programs in many developed markets. Online pharmacies comprised 23% of the distribution landscape in 2024 and are expected to grow rapidly, with a forecasted CAGR of 10.4% from 2025 to 2030. The rise of e-health platforms, chronic care subscription services, and direct-to-consumer medication delivery is transforming patient access and enhancing adherence, especially in urban and digitally connected populations. This trend aligns with broader shifts in healthcare toward remote management and digital engagement, positioning online channels as a key growth frontier for Victoza’s distribution strategy.

Regional Analysis

The North American market remains the most significant contributor to Victoza’s global revenue, with a market size of USD 2.8 billion in 2024, projected to reach USD 3.9 billion by 2030, growing at a CAGR of 5.7%. The United States dominates the region, driven by early adoption of GLP-1 therapies, favorable reimbursement structures, and a high prevalence of obesity and type 2 diabetes. In addition, recent developments in biosimilar production particularly partnerships between Teva Pharmaceuticals and Alvotech are expected to introduce price competition, potentially expanding patient access while reshaping the pricing dynamics of the market. These factors, combined with robust clinical infrastructure and widespread physician awareness, ensure that North America remains a core market for Victoza through the forecast period.

Europe Market Trends

In Europe, the Victoza market stood at USD 1.5 billion in 2024 and is anticipated to grow to USD 2.0 billion by 2030 at a CAGR of 5.6%. The region benefits from strong public healthcare systems and a history of GLP-1 therapy integration into standard diabetes care. Germany, the United Kingdom, and France lead demand, supported by comprehensive reimbursement policies and early adoption of combination therapies. Meanwhile, the Asia-Pacific region is experiencing the fastest growth, with a market size of USD 0.6 billion in 2024 expected to nearly double to USD 1.1 billion by 2030, reflecting a robust CAGR of 10.2%. Key drivers include the rapid increase in diabetes prevalence in China and India and the anticipated introduction of lower-cost liraglutide biosimilars, which are critical to improving access in price-sensitive markets.

In Latin America, the Victoza market was valued at USD 0.25 billion in 2024 and is forecast to reach USD 0.42 billion by 2030, registering a CAGR of 8.8%. The region faces a high unmet need for effective diabetes treatment, and countries such as Mexico and Brazil are advancing public health initiatives aimed at improving chronic disease management. Gradual expansion of universal health coverage and public-private partnerships are expected to support market growth. Lastly, the Middle East & Africa region is poised for rapid expansion, growing from USD 0.15 billion in 2024 to USD 0.35 billion in 2030 at a remarkable CAGR of 12.7%. The surge is fueled by an increasing burden of non-communicable diseases, shifting dietary patterns, and government-led efforts to combat diabetes through national health strategies. While infrastructure challenges remain, the potential for growth in this region is substantial, particularly with increased pharmaceutical investments and awareness campaigns.

List of key players in Clay Roof Tiles Market

1. Novo Nordisk A/S
2. Teva Pharmaceutical Industries Ltd.
3. Alvotech
4. Sandoz (a Novartis division)

Recent Developments

• Teva & Alvotech (2023): Teamed up to develop and commercialize a biosimilar version of liraglutide, challenging Victoza’s exclusivity in the U.S.

• Novo Nordisk Pediatric Expansion (2024): FDA expanded Victoza’s indication for children aged 10+, broadening its market scope.

• EHR Integration (2024): Victoza incorporated into major electronic health record platforms for automated therapy recommendations in the U.S. and EU.

• Real-World Evidence (2025): A multinational study showed Victoza reduced hospitalization rates by 18% in cardiovascular patients, reinforcing prescriber confidence.